20:42 , Oct 31, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 30 genomic loci could help predict the risk of schizophrenia. Genome-wide association studies in 47,559 schizophrenia patients and 70,936 healthy volunteers identified associations between the disease and SNPs on 30 loci,...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-31 (miR-31); neuronal nitric oxide synthase 1 (NOS1; nNOS)

Cardiovascular disease INDICATION: Fibrillation Cell culture and goat studies suggest inhibiting miR-31 could help treat atrial fibrillation (AF). miR-31 levels were higher in atrial myocytes from AF patients and in the left ventricle of a...
07:00 , Jun 14, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) In vitro and mouse studies suggest iNOS inhibitors could...
07:00 , Oct 6, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neuronal nitric oxide synthase 1 (NOS1; nNOS) Rat and tissue culture studies identified 3,6-disubstituted indole derivative-based nNOS inhibitors that could help treat neuropathic pain....
08:00 , Dec 9, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Discs large homolog 4 (DLG4; PSD95); neuronal nitric oxide synthase 1 (NOS1; nNOS) Rodent studies suggest that inhibiting interactions between nNOS and PSD95 in...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

NXN-188: Phase II data

The double-blind, U.S. Phase II Study 204 trial in 174 patients with moderate to severe acute migraine headache without aura showed that a single dose of oral 600 mg NXN-188 missed the primary endpoint of...
08:00 , Mar 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Musculoskeletal disease Duchenne muscular dystrophy (DMD) Dystrophin (DMD); nitric oxide synthase 1 (neuronal) (NOS1; nNOS) Ex vivo and mouse studies suggest...
08:00 , Nov 6, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Fatigue Neuronal nitric oxide synthase (nNOS) Studies in mice suggest that increasing levels of sarcolemma-localized nNOS could be useful for lowering...
07:00 , Mar 27, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ras; nitric oxide synthase 3 (NOS3; eNOS) A study in cell culture and mice suggests that antagonizing eNOS might treat...
08:00 , Nov 19, 2007 |  BioCentury  |  Emerging Company Profile

Corporate Profile

NeurAxon Inc. Waltham, Mass. Technology: Neuronal nitric oxide synthase ( nNOS ) inhibitors Disease focus: Neurology Clinical status: Phase I Founded: 2004 by Suman Rakhit, John Andrews and Shawn Maddaford University collaborators: University of Arizona...